Publication | Open Access
SARS-CoV-2 infection induces the production of autoantibodies in severe COVID-19 patients in an age-dependent manner
12
Citations
60
References
2022
Year
Unknown Venue
ImmunodeficienciesImmunologySevere Covid-19 PatientsAutoantibody LevelsDistinct Autoantibody LevelsAge-dependent MannerCovid-19 EpidemiologyImmune SystemAutoimmune Liver DiseaseCovid-19Viral PersistenceAutoinflammatory DisordersAutoantibodiesPublic HealthAutoinflammatory DiseaseLong CovidAutoimmune DiseaseCovid-19 PandemicAutoimmunityHumoral ImmunityAutoimmune ResearchImmune FunctionImmunologic DiseaseChronic Viral InfectionEpidemiologyCardiovascular DiseaseSars-cov-2 InfectionAutoantibody ProductionAbstract AgeMedicine
ABSTRACT Age is a significant risk factor for the coronavirus disease 2019 (COVID-19) outcomes due to immunosenescence and certain age-dependent medical conditions (e.g., obesity, cardiovascular disorder, diabetes, chronic respiratory disease). However, despite the well-known influence of age on autoantibody biology in health & disease, its impact on the risk of developing severe COVID-19 remains poorly explored. Here, we performed a cross-sectional study of autoantibodies directed against 58 targets associated with autoimmune diseases in 159 individuals with different COVID-19 outcomes (with 71 mild, 61 moderate, and 27 severe patients) and 73 healthy controls. We found that the natural production of autoantibodies increases with age and is exacerbated by SARS-CoV-2 infection, mostly in severe COVID-19 patients. Multivariate regression analysis showed that severe COVID-19 patients have a significant age-associated increase of autoantibody levels against 16 targets (e.g., amyloid β peptide, β catenin, cardiolipin, claudin, enteric nerve, fibulin, insulin receptor a, and platelet glycoprotein). Principal component analysis with spectrum decomposition based on these autoantibodies indicated an age-dependent stratification of severe COVID-19 patients. Random forest analysis ranked autoantibodies targeting cardiolipin, claudin, and platelet glycoprotein as the three most crucial autoantibodies for the stratification of severe elderly COVID-19 patients. Follow-up analysis using binomial regression found that anti-cardiolipin and anti-platelet glycoprotein autoantibodies indicated a significantly increased likelihood of developing a severe COVID-19 phenotype, presenting a synergistic effect on worsening COVID-19 outcomes. These findings provide new key insights to explain why elderly patients less favorable outcomes have than young individuals, suggesting new associations of distinct autoantibody levels with disease severity.
| Year | Citations | |
|---|---|---|
Page 1
Page 1